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ErbB2 is a prognostic factor and target of therapy for
many carcinomas. In contrast with the other ErbB recept-
ors, ErbB2 lacks a soluble direct ligand, but it is the pre-
ferred co-receptor for the ErbB family members, forming
heterodimers with more potent and prolonged signalling
activity than that of homodimers. We recently produced a
new anti-ErbB2 antibody, Erb-hcAb, by fusion of Erbicin,
a human, anti-ErbB2 scFv, selectively cytotoxic to ErbB2-
positive cells, and a human Fc domain. This fully human
antitumour antibody represents a compact version of an
IgG1, with the cytotoxicity of the scFv moiety on target
cells, combined with the ability of the Fc moiety to induce
both antibody- and complement-dependent cytotoxicity.
Here, we describe the main properties of Erb-hcAb, using
as a reference Herceptin, an anti-ErbB2 humanized mono-
clonal currently employed in clinical immunotherapy. We
found that both bivalent Erb-hcAb and Herceptin increase
receptor phosphorylation and downregulation, whereas
monovalent Erbicin does not. These results correlate with
the finding that Erb-hcAb is capable of inducing apoptosis
and inhibiting cell cycle progression in ErbB2-positive
cells. Its powerful in vitro antitumour action matched
that observed in vivo in experiments with human ErbB2-
positive tumour xenografts established in athymic mice.
Finally, Erb-hcAb displays a glycosylation profile virtually
superimposable to that of a human IgG. These findings
suggest that Erb-hcAb is a very promising new agent for
the immunotherapy of carcinomas that overexpress the
ErbB2 receptor.
Introduction
There is a major interest in considering the overexpression of
the ErbB2 receptor as a prognostic factor and target in therapy
for breast carcinoma and other carcinomas, such as those of
bladder, lung, colon, stomach and pancreas (1–3). In contrast
with the other receptors of the ErbB family, ErbB2 lacks a
soluble direct ligand, but it is the preferred co-receptor for its
family members, namely ErbB-1, ErbB-3 and ErbB-4 (4). The
ErbB receptor heterodimers that contain ErbB2 show higher
ligand affinity and lower rate endocytosis than homodimers,
hence engender a more potent and prolonged signalling activ-
ity (5). Furthermore, once internalized, heterodimers are tar-
geted for recycling to the cell surface, where they can undergo
another cycle of activation; homodimers instead are destined
for degradation (6).
Recent studies propose that anti-ErbB2 antibodies can trig-
ger endocytosis of the receptor through homodimerization
(7,8). Once internalized, the ErbB2 homodimers can recruit
Cbl ubiquitin ligase and are routed to the degradation pathway
(9). Thus, antibodies can promote the degradation of ErbB2
and remove ErbB2 from the cell surface. A reduced level of
ErbB2 at the cell surface induces a decreased formation of
ErbB2 heterodimers, resulting in a reduced growth factor-
induced signalling and cell proliferation.
We recently developed a new anti-ErbB2 antibody from a
human, per se cytotoxic single chain variable fragment (scFv)
(10) and a human Fc domain. This fully human antitumour
antibody (named Erbicin-derived human, compact antibody or
Erb-hcAb) represents a compact, reduced version of an IgG1,
with the antiproliferative effect of the scFv moiety on tumour
target cells, combined with the ability of the Fc moiety to
induce both antibody-dependent cellular cytotoxicity (ADCC)
and complement-dependent cytotoxicity (CDC) (11). Based
on previous studies (12–14), such a compact antibody is
expected to have the advantage of the prolonged half-life of
an antibody, composed with an increased extravascular dif-
fusion, both very expedient features for targeting solid
tumours.
A recombinant, human scFv-Fc antibody has been already
reported (14) to endure a much longer serum half-life in vivo
when compared with its parental scFv. However, the protein
was produced in yeast with yeast controlled glycosylation;
furthermore, it was not characterized, as it was obtained in
very low yields, and found to be heterogeneous, i.e. only
partially glycosylated. It should be noted that Erb-hcAb was
prepared instead in CHO cells, a mammalian model certainly
closer than yeast to human cells.
Here, we describe the main properties of Erb-hcAb, a human,
compact antibody. Our results suggest that this new antibody is
a very promising agent for the immunotherapy of carcinomas
that overexpress the ErbB2 receptor.
Materials and methods
Antibodies
The antibodies used in the current study were the following: murine anti-
phosphotyrosine monoclonal antibody (mAb) P-Tyr (PY99) (Santa Cruz Bio-
technology, Santa Cruz, CA); rabbit polyclonal anti-ErbB2 immunoglobulin
Abbreviations: ADCC, antibody-dependent cellular cytotoxicity; CDC,
complement-dependent cytotoxicity; Erb-hcAb, Erbicin-derived human,
compact antibody; FACS, fluorescence-activated cell sorting; FITC,
fluorescein-isothiocyanate; HRP, horseradish peroxidase; mAb, monoclonal
antibody; MALDI, matrix-assisted laser desorption ionization; PBS,
phosphate-buffered saline; PNGase F, peptide N-glycosidase F; PSD, post
source decay; scFv, single chain variable fragment.
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antibody (Neu C-18) (Santa Cruz Biotechnology); murine anti-actin mAb
(Sigma, St Louis, MO); Herceptin (Genentech, South San Francisco, CA);
horseradish peroxidase (HRP) conjugated goat anti-rabbit immunoglobulin
antibody (Pierce, Rockford, IL); HRP-conjugated rabbit anti-mouse immuno-
globulin antibody (Pierce).
Cell cultures
MDA-MB 361 cells (kindly provided by Dr N.Normanno, Cancer Institute of
Naples), SKBR3 cells (from American Type Culture Collection, Rockville,
MD), both from human breast carcinomas, and the A431 cell line from human
epidermoid carcinoma (from American Type Culture Collection) were cul-
tured in RPMI 1640 (Gibco BRL, Life Technologies, Paisley, UK) supple-
mented with 10% foetal bovine serum, 50 U/ml penicillin and 50 mg/ml
streptomycin (all from Gibco BRL).
Cell lysis and immunoblotting analyses
SKBR3 cell lysates were prepared by resuspending in 0.1 ml lysis buffer
(10 mM Tris–HCl, pH 7.4, 150 mM NaCl and 0.5% Nonidet P-40 containing
Complete proteases inhibitor) (Boehringer Mannheim, Germany) about 1
106 cells, previously detached with the cell dissociation solution (Sigma), and
washed three times in phosphate-buffered saline (PBS). After 20 min, at
0C the extracts were clarified by centrifugation at 12 000 r.p.m. for 15 min.
Protein concentration was determined by a colorimetric assay (Bradford,
Sigma), and aliquots of 20 mg were run on 7.5% SDS–PAGE, followed by
electroblotting onto PVDF membranes (Millipore, Bedford, MA). The ErbB2
protein was detected using the anti-ErbB2 sc-284 mAb (Santa Cruz), followed
by rabbit anti-mouse horseradish peroxidase-conjugated antibody. The signal
intensity of reactive bands was quantitatively measured with a phosphorimager
(GS-710; Bio-Rad, Hercules, CA).
Determination of ErbB2 phosphorylation
SKBR3 cells were grown at 37C in 6-well plates, starved for 24 h in serum-
free RPMI medium, then treated with scFv, Erb-hcAb or Herceptin (each at a
concentration of 200 nM), in fresh, serum-free medium. After the indicated
time periods, cells were washed with PBS, harvested and lysed in the presence
of 1 mM sodium orthovanadate (Sigma), as described above. Immunoblotting
analyses were performed with an anti-phosphotyrosine mAb. The signal
intensity of reactive bands was quantified with a phosphorimager (GS-710;
Bio-Rad).
The data were normalized to those obtained for the same extracts using an
anti-actin mAb (Sigma).
Downregulation assay
SKBR3 cells were plated at a density of 6  105 in 6-well plates. After 24 h,
the medium was replaced by methionine-free medium containing 100 mCi
[35S]methionine per ml and 2% fetal bovine serum. The cells were metabolic-
ally labelled for 16 h and then incubated with scFv, Erb-hcAb or Herceptin
(each at a concentration of 200 nM) in fresh medium containing unlabelled
methionine. After 16 h, whole cell lysates were prepared and equal amounts,
determined by c.p.m. measurement, were subjected to immunoprecipitation
with the C-terminal-specific anti-ErbB2 antibody Neu C-18 (Santa Cruz) and
with anti-actin mAb (Sigma). The immune complexes were collected by
adsorption to protein A-Sepharose beads (Sigma) for 1 h at 4C, then washed
and released by boiling in loading buffer. Samples were separated by electro-
phoresis on a 7.5% SDS–PAGE, and analysed by autoradiography.
The band intensities were quantified by using a scanner (Molecular Imager
FX, Biorad).
Cell cycle analysis
SKBR3 cells were seeded in 6-well plates at a density of 6 105 and incubated
at 37C with Erb-hcAb or Herceptin at a concentration of 100 or 200 nM. After
3 days, cells were detached with the cell dissociation solution (Sigma), washed
with PBS and resuspended in PI staining buffer (50 mg/ml propidium iodide,
0.1% NP-40 and 10 mg/ml RNase A). Following 30 min of incubation at room
temperature, cell cycle analysis was performed on a FACS Calibur Flow
Cytometer (Becton Dickinson, Oxford, UK). The percentage of cells in each
phase of the cell cycle (G1, S and G2/M) was calculated by using Modfit
software (Becton Dickinson), and compared with the results obtained with
control untreated cells.
Detection of apoptosis
To test apoptotic death, SKBR3 cells were seeded in 6-well plates at a density
of 6  105/well, in the absence or in the presence of Erb-hcAb or Herceptin
(each at a concentration of 200 nM). After 24 or 40 h, cells were harvested,
washed in PBS, and treated with Annexin V-FITC following resuspension in
binding buffer [10 mM HEPES (pH 7.4), 140 mM NaCl and 2.5 mM CaCl2].
Cells were then stained with propidium iodide according to the manufacturer’s
recommendations (Becton Dickinson). Labelled cells were analysed using the
FACS Calibur flow cytometer (Becton Dickinson); the data were processed
using CellQuest software (Becton Dickinson).
The apoptotic inducer puromycin (10 mg/ml) was used as a positive control.
Cytotoxicity assays
Cells were seeded in 96-well plates at a density of 1.5 104/well in 150 ml, and
Erb-hcAb was added at increasing concentrations. After 72 h, cell viability was
determined in triplicate using the ATPlite 1 step test (Perkin Elmer, Cologno
Monzese, Italy). The resulting luminescence was measured in a microplate
counter (Multilabel Counter Victor 3, Perkin Elmer). Cell survival was
expressed as percent of viable treated cells with respect to control untreated
cultures. Typically, SD values were55%.
In vivo antitumour activity
In vivo experiments were performed with 5-week-old female Balb/cByJIco-
nu/nu mice (Charles River laboratories, Calco, Italy). MDA-MB 361 cells
(5  105) were suspended in 0.2 ml sterile PBS and injected subcutaneously
(day 0) in the right paw. At day 11, when tumours were clearly detectable,
Erb-hcAb dissolved in PBS was administered intraperitoneally at doses of
1.5 mg/kg of body wt for seven times at 72 h intervals. Equimolar doses of
Herceptin (2.25 mg/kg of body wt) were administered intraperitoneally to a
second group of animals. Another group of control mice was treated with
identical volumes of sterile PBS. During the period of treatment, tumour
volumes (V) were measured with calliper and calculated by the formula of
rotational ellipsoid V ¼ A  B2/2 (A is the axial diameter and B the rotational
diameter). SD values were 510%. All mice were maintained at the animal
facility of the Department of Cellular and Molecular Biology and Pathology,
University of Naples Federico II. The animal experimentations described
herein were conducted in accordance with the Italian regulation for experi-
mentation on animals. All in vivo experiments were carried out with
ethical committee approval and met the standards required by the UKCCCR
guidelines (15).
Chemical and enzymatic hydrolyses
Trypsin, dithiothreitol and iodoacetamide were purchased from Sigma. Peptide
N-glycosidase F (PNGase F) was obtained from Roche (Mannheim, Germany).
Pre-packed PD-10 gel filtration cartridges were from Pharmacia (Cologno
Monzese, Italy). Pre-packed Sep pak C18 cartridges were purchased from
Waters (Milano, Italy). All other reagents and solvents were of the highest
purity available from Carlo Erba (Rodano, Italy).
ERB-hcAb (500 mg) was reduced and alkylated as previously described (16)
and digested with trypsin in 50 mM ammonium bicarbonate (pH 8.5), over-
night at 37C using 1:50 enzyme/substrate ratio (w/w). Samples were then
diluted with water and lyophilized. Deglycosylation of the peptide mixtures
was performed by treatment with PNGase F in 50 mM ammonium bicarbonate
(pH 8.5), overnight at 37C using 0.1 U of enzyme per 500 mg of protein.
N-linked oligosaccharide chains were separated from peptides by reverse
phase chromatography on prepacked Sep-pak cartridges.
Mass spectrometry
Positive MALDI/MS (matrix-assisted laser desorption ionization) analyses and
MALDI/PSD (post source decay) experiments were carried out on a Voyager
DE-Pro instrument operating in reflectron mode (Applied Biosystems,
Framingham, MA). The MALDI matrices were prepared by dissolving 10 mg
of 2,5-dihydroxybenzoic acid in 1 ml methanol or 10 mg a-cyano in 1 ml of
acetonitrile/0.2% trifluoroacetic acid (70:30 v/v). Typically, 1 ml of matrix was
applied to the metallic sample plate and 1 ml of analyte was then added.
Acceleration and reflector voltages were set up as follows: target voltage at
20 kV, first grid at 66% of target voltage, delayed extraction at 200 ns. The
PSD fragment spectra were acquired after pseudo-molecular cation selection
using the time ion selector. Fragment ions were refocused by stepwise reduc-
tion of the reflector voltage by 20%.
The individual segments were then stitched together using the Applied
Biosystems software. Raw data were analysed using the computer software
provided by the manufacturers and are reported as monoisotopic masses.
Results
Structural characterization of Erb-hcAb
Erb-hcAb, the compact version of a human anti-ErbB2 anti-
body, i.e. an immunoglobulin-like IgG1 protein with a reduced
molecular weight, was prepared as previously described (11).
The resulting construct preserves all functionally relevant anti-
body regions, even though it lacks the CH1 and CL domains
with respect to a full-size immunoglobulin, such as Herceptin
A human compact anti-ErbB2 antibody
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(Figure 1). When the compact antibody was analysed by SDS–
PAGE (Figure 2), it was found to migrate under non-reducing
conditions with a reduced molecular size of 100 kDa
compared with that of Herceptin (155 kDa).
An ideal antibody for immunotherapy should not only con-
tain a reduced convenient molecular size, but also human-type
glycan structures, hence increased half-life and biological
activity, and low or absent immunogenicity. The structure of
the glycosidic moieties of Erb-hcAb was investigated by direct
MALDI/MS analysis of the oligosaccharide mixtures in posi-
tive ion mode. Figure 3A shows the mass signals recorded in
the spectra and the corresponding oligosaccharide structures
inferred byMS data. The glycans N-linked to Erb-hcAb belong
to the complex type consisting essentially of fucosylated and
non-fucosylated biantennary structures.
The ultimate definition of the different glycans structures
including the sequence and branching degree of the antennae
was achieved by tandem mass spectrometry experiments using
the MALDI/PSD technique. Individual ions corresponding to
the different glycoforms were isolated and fragmented in PSD
mode. The characteristic PSD fragmentation pattern, mainly
due to ring cleavages and to A-type cleavages occurring at the
non-reducing end of N-acetylglucosamine residues, led us to
the definition of the structure of glycoforms. As an example,
Figure 4 shows the PSD spectrum of Erb-hcAb, obtained by
selecting the precursor ion at m/z 1647.2. The mass spectrum
exhibited a simple fragmentation pattern in which the
complete series of Y ions allowed immediate assignment of
the full monosaccharide sequence. The B5 ion at m/z 1279.6
resulting from the cleavage of the glycosidic bond between the
two N-acetylhexosamine core residues led to the localization
of the fucose moiety on the first HexNAc.
As shown in Figure 3, the glycosylation profile of Erb-hcAb
(panel A) is very similar to that observed for human serum IgG
Fig. 2. Analysis of purified Erb-hcAb by SDS–PAGE. Erb-hcAb (lane 2),
and Herceptin (lane 1) were run by SDS–PAGE under non-reducing
conditions.
Fig. 3. Glycosylation profile of Erb-hcAb. Mass spectra of glycans from
Erb-hcAb (A) and a human serum IgG (B). Panel B was provided by courtesy
of Crucell Holland B.V., Leiden, The Netherlands.
Fig. 1. Schematic representation of Erb-hcAb and Herceptin. (A) Erb-hcAb,
a human compact anti-ErbB2 antibody; (B) Herceptin, a full-size IgG. VH
and VL are the heavy and light chain variable domains, respectively. H,
the hinge region with disulfide bridges. CH1, CH2, CH3 are the heavy chain
constant domains, and CL is the light constant domain of a human IgG1.
Fig. 4. MALDI/PSD spectrum of the m/z 1647.2 ion recorded from
Erb-hcAb glycoforms. The Y and B ion series are indicated. Fragmentation
events are reported on the glycosidic structure.
C.De Lorenzo et al.
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(panel B). Levels of galactosylation are equivalent to those
seen in human IgG (0-galactose/1-galactose/2-galactose in
the ratio 1/2/1). Core fucose is also present and no hybrid
structures or high-mannose structures are detectable.
Effects on ErbB2 phosphorylation
The effects of ERB-hcAb were compared with those of
Erbicin, the parental scFv, used as a negative control, and of
Herceptin, a humanized anti-ErbB2 mAb currently used for
the therapy of breast carcinoma, used as a positive control. Cell
extracts of starved SKBR3 cells, treated at 37C for various
time intervals with the immunoagents (200 nM), were ana-
lysed by western blottings, using an anti-P-Tyr mAb. The
analyses were performed in the presence of an anti-actin
mAb to directly compare the levels of ErbB2 receptor phos-
phorylation. The signal intensity of positive bands was esti-
mated by phosphorimaging. Figure 5 illustrates the results of
one of these experiments: Erb-hcAb, as well as Herceptin,
effectively stimulate phosphorylation of ErbB2. This is appar-
ently due to their bivalent format and consequent ability to bind
two receptors, because monovalent Erbicin does not increase
phosphorylation (Figure 5), as it cannot bind simultaneously
two receptor molecules and is unable to form homodimers.
Effects of Erb-hcAb on ErbB2 levels
One possible mechanism underlying the antiproliferative
effects of anti-ErbB2 antibodies is downregulation of the
receptor (7,17). We thus analysed whether the effects of the
Erbicin-derived compact antibody on tumour cell growth
could be attributed to lower ErbB2 levels generated by an
increased receptor turnover as triggered by antibody binding.
The effects of Erb-hcAb on turnover of ErbB2 was measured
on metabolically labelled SKBR3 cells, treated for 16 h with
the parental scFv (200 nM), Erb-hcAb (200 nM) or Herceptin
(200 nM) used as a control. The receptor was immunopre-
cipitated with an anti-ErbB2 mAb from aliquots of lysate
containing equal amounts of radioactivity, and analysed by
SDS–PAGE followed by autoradiography.
Densitometric evaluation of the data showed that the level
of ErbB2 was reduced by 40–50% after exposure of SKBR3
cells to Herceptin or Erb-hcAb (Figure 6), whereas no effects
were detected upon treatment with the monovalent scFv. This
suggests that the bivalent compact antibody has acquired,
with respect to the monovalent scFv, the ability to effectively
induce the degradation of the receptor.
Determination of nature of the tumour cell death
To determine whether the mechanism of cell death occurs
through induction of apoptosis, we used annexin V to measure
the appearance of phosphatidylserine, a marker of apoptosis,
on the outer leaflet of the plasma membrane of SKBR3 cells.
Cells treated with Erb-hcAb, as well as those treated with
Herceptin, were found to bind more FITC-conjugated annexin
V than untreated cells (Table I). These results show that the
nature of cell death as induced by Erb-hcAb is apoptotic.
Effects of Erb-hcAb on cell cycling of ErbB2-overexpressing
cells
To test whether a growth arrest contributes to the antitumour
action of Erb-hcAb, SKBR3 cells were treated with Erb-hcAb,
or Herceptin, for 72 h at 37C, and then subjected to cell cycle
analysis by flow cytometry.
As shown in Table II, Erb-hcAb significantly reduces the
percentage of SKBR3 cells undergoing S-phase and produces
Fig. 5. The effects of Erb-hcAb on ErbB2 phosphorylation. Upper panel:
western blotting analyses with an anti-phosphotyrosine mAb of lysates from
SKBR3 cells, untreated (lane 1) or treated for 90 min or 3 h with Erb-hcAb
(lanes 2 and 3), Erbicin (lanes 4 and 5) or Herceptin (lanes 6 and 7).
Lower panel: the levels of ErbB2 phosporylation are reported as percentages
of the phosphorylation level detected in untreated cells.
Fig. 6. Turnover of the ErbB2 receptor in SKBR3 cells treated with
Erb-hcAb. (A) Autoradiograms of immunoprecipitated radioactive ErbB2
from lysates of SKBR3 cells untreated or treated as indicated for
16 h with Erb-hcAb, Erbicin or Herceptin. Equal amounts (c.p.m.) of
35S-labelled lysates were used. (B) Co-immunoprecipitation of ErbB2 and
actin, performed for normalization. (C) The levels of ErbB2 are reported
as percentages of the level detected in untreated control cells.
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an accumulation of cells in G0/G1 phase. The effect of
Erb-hcAb on the cell cycle is dose-dependent, with a stronger
inhibitory effect occurring at higher antibody concentra-
tions (Table II). Similar results were obtained with Herceptin
(Table II), used as a positive control.
In vivo antitumour activity of Erb-hcAb
SKBR3 cells, used for in vitro characterization of Erb-hcAb,
are not tumorigenic in athymic mice (18), hence for in vivo
studies Erb-hcAb was tested on the ErbB2-positive MDA-MB
361 tumour cells from human mammary carcinoma (19). The
level of ErbB2 expression in the latter cells was found to be
comparable to that measured in SKBR3 cells when a quanti-
tative analysis by western blotting was performed on lysates
from the two cell types. In line with this finding, the antitu-
mour effect of Erb-hcAb on the latter cell line (data not shown)
was found to be similar to that previously reported for SKBR3
cells (11).
As shown in Figure 7, the treatment of mice bearing
MDA-MB 361 tumours with 7 doses, at 72 h intervals, of
1.5 mg/kg of body wt of Erb-hcAb induced a dramatic reduc-
tion in tumour volume. No growth inhibition was observed in
untreated mice (data not shown), or in mice treated with PBS
(Figure 7). We tested in a parallel experiment the effects of
equimolar doses of Herceptin (2.25 mg/kg of body wt) on the
same experimental model. The antitumour effect of Herceptin,
when compared with that of Erb-hcAb, was found to be less
effective (Figure 7). During the period of treatment the animals
did not show signs of wasting or other visible signs of toxicity.
Discussion
The understanding of the molecular basis of the mechanism of
action of an immunoagent is essential for its exploitation as an
antitumour agent. In the present study, we have examined
the biological effects of Erb-hcAb on ErbB2-positive cells in
comparison with a well-characterized, humanized anti-ErbB2
antibody, such as Herceptin, currently used for treatment of
advanced breast cancer (20,21).
Previously, an antineoplastic effect of Erb-hcAb stronger
than that of Herceptin was observed (11) on tumours similar
to the alveolar-type human lobular mammary carcinomas, as
induced in mice inoculated with murine TUBO cells (22).
In the experiments reported here, we tested for the first time
Erb-hcAb on human ErbB2-positive tumour xenografts estab-
lished in athymic mice. To directly compare the antitumour
efficacy of this novel immunoagent with that of Herceptin, we
tested in parallel experiments, the effects of equimolar doses of
Herceptin on the same experimental model. We found that
Erb-hcAb completely inhibited the growth of tumours during
the course of treatment, and its effect was significantly more
potent than that of Herceptin.
This finding deserves to be commented upon, especially
because the affinity of Erb-hcAb for ErbB2 (Kd ¼ 1 nM)
is of the same order as that of Herceptin [Kd ¼ 5 nM, see
ref. (11)]. However, Erb-hcAb is of a smaller size than
Herceptin (100 versus 155 kDa), a property which has been
shown to promote an increased extra-vascular diffusion and
tumour penetration (12,13). It may not be excluded that the
ability of Erb-hcAb to induce CDC, a characteristic which is
not shared by Herceptin (11,23), might play a role in the higher
effectiveness of Erb-hcAb as an antitumour agent in vivo.
We found on the other hand that both antibodies, Erb-hcAb
and Herceptin, induce a similar increase in the phospho-
tyrosine content of ErbB2. The ability of antibodies to affect
the extent of ErbB2 phosphorylation reflects their capacity
to induce homodimerization of ErbB2 (17). This presumably
leads to its downregulation and degradation. In this respect,
we observed a strong reduction of the cellular level of ErbB2
in cells treated with Erb-hcAb.
It is likely that downmodulation of the receptor results
from the ability of bivalent Erb-hcAb to cross-link cell surface
Table I. Extent of apoptosis in SKBR3 cells treated for 24 or 40 h with
Erb-hcAb or Herceptin
Apoptotic cells (%) MFIa ratio
(treated/control cells)
24 h 40 h
Control cells 3 5 1
Erb-hcAb 19 31 2
Herceptin 12 32 2
Puromycinb 41 2.3
aMFI is the mean fluorescence intensity measured by flow cytometry analyses
after treatment of SKBR3 cells with FITC-conjugated Annexin V.
bPuromycin (10 mg/ml) was used as a positive control.
Table II. Cell cycle analyses of SKBR3 cells treated with Erb-hcAb or
Herceptin
G0/G1 (% cells) S (% cells) G2/M (% cells)
Control 78.7 18.2 3.04
Erb-hcAb (200 nM) 87.15 10.6 2.16
Erb-hcAb (400 nM) 90.52 7.6 1.87
Herceptin (200 nM) 87.04 9.49 3.47
Herceptin (400 nM) 89.26 7.95 2.79
Fig. 7. In vivo inhibition of tumour growth by Erb-hcAb. Tumour growth
was measured in mice inoculated subcutaneously with MDA-MB 361 cells
from human mammary carcinoma. Treated mice (open circles) were injected
with Erb-hcAb at doses of 1.5 mg/kg of body weight, starting at day 11.
Injections were repeated seven times at 72 h intervals as indicated by the
arrows. Control mice were treated with sterile PBS solution (black circles),
or equimolar doses of Herceptin (open triangles).
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receptors, since Erbicin, as a monovalent scFv, does not
increase ErbB2 phosphorylation, or its degradation.
The downstream effects of antibody-induced down-
regulation of ErbB2 could translate to signals that inhibit
progression through the cell cycle and enhance apoptosis.
Consistent with this hypothesis is the finding reported here
that Erb-hcAb is capable of inducing apoptosis and inhibiting
cell cycle progression in ErbB2-positive cells.
According to previous studies (24,25), another property
of interest to define the potential of Erb-hcAb as an anti-
carcinoma immunoagent is the glycosylation of the antibody.
We found that the glycosylation profile of Erb-hcAb is virtu-
ally superimposable on that of a human IgG. This finding
can strengthen the suggestion of a low degree, or absence, of
host-defence reactivity in human patients toward Erb-hcAb,
an immunoagent of human origin.
These promising findings suggest that Erb-hcAb could be a
new, potentially effective and safe antitumour drug.
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